ERBB2 and breast carcinoma: We have demonstrated in this study that metastatic TNBC cells, MDA-MB-436 (BRCA1- deficient), MDA-MB231, and MDA-MB-468, were all sensitive to Talazoparib, a PARPi that has been approved to treat HER2- breast cancer with BRCA-mutations.